Top Markets
#1 Black Phoenix Black Phoenix +355.13%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.86%
#4 OpenEden OpenEden +60.23%
#5 Akedo Akedo +56.95%
#6 BasedHype BasedHype +26.68%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.51%
#9 Humanity Humanity +19.18%
#10 Ether.fi Ether.fi +17.32%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rang in aandelen #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aandeelprijs
$0.01292666
Laatst gesynchroniseerd: 2025-04-08
Marktkapitalisatie
$157.54K
Verandering (1 dag)
6.84%
Verandering (1 jaar)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Categorie

Healthcare
P/S-ratio voor Synairgen plc (SNG)
P/S-ratio op August 2026 TTM: 0.00
Volgens de meest recente financiële rapporten en aandelenkoers van Synairgen plc is de huidige P/S-ratio (TTM) 0.00. Eind 2022 had het bedrijf een P/S-ratio van 0.00.
P/S-ratiohistoriek voor Synairgen plc van 2004 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 86.19K 5,474.43%
2017 1.55K 0.00%
2016 0.00 -100.00%
2015 589.54K 12,229.42%
2014 4.78K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 68.65 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 134.85 -99.56%
2006 30.85K 158.87%
2005 11.92K 8,695.11%
2004 135.48 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE